跳至主要内容
临床试验/NCT03404310
NCT03404310终止不适用

Oral Zinc Sulfate for the Treatment of High Risk Cervical HPV Versus Placebo

Spectrum Health Hospitals2 个研究点 分布在 1 个国家目标入组 21 人开始时间: 2017年10月24日最近更新:
适应症

试验速览

阶段
不适用
状态
终止
入组人数
21
试验地点
2
主要终点
Clearance rates of high risk HPV

研究概览

简要总结

The Human Papillomavirus (HPV) is well established as the primary causative agent in both warts and cervical cancer. Although cervical high risk HPV (hrHPV) infections have a high rate of spontaneous resolution this takes time and the infection can cause cervical cells to progress to precancerous and cancerous lesions. Zinc has been shown to play a central role in immunity. This study is to determine if oral zinc sulfate can improve clearance rates of high risk HPV versus placebo.

详细描述

Upon enrollment eligible participants will be randomized and given a three-month supply of zinc sulfate or placebo to be taken as directed. They will have zinc serum lab testing at enrollment and upon study completion. Patients will also be asked to complete short questionnaires and to make study staff aware of any side effects they should experience.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

盲法说明

Single-blinded placebo controlled

入排标准

年龄范围
21 Years 至 65 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Abnormal cytology of atypical squamous cells of undetermined significance (ASCUS) on Pap smear OR
  • Low-grade squamous intra epithelial lesions (LSIL) on Pap smear OR
  • Positive hrHPV on routine screening (positive HPV will be assumed to be high grade)

排除标准

  • Patients who proceed to excisional procedures (loop electrosurgical excision procedure or cold knife conization)
  • Pregnant patients
  • Breastfeeding patients
  • Immunocompromised patients

结局指标

主要结局

Clearance rates of high risk HPV

时间窗: During 3 month treatment period

次要结局

  • Low Zinc Levels and Persistence(After 3 month treatment period)
  • Side Effects(After 3 month treatment period)
  • Compliance Rates(After 3 month treatment period)
  • Parity(After 3 month treatment period)
  • Progression versus Regression(During 3 month treatment period)
  • Zinc Levels and Regression(After 3 month treatment period)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验